140 related articles for article (PubMed ID: 35644299)
21. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
23. Targeting HDACs for diffuse large B-cell lymphoma therapy.
Wu C; Song Q; Gao S; Wu S
Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
[TBL] [Abstract][Full Text] [Related]
24. Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells.
Deng J; Hou B; Hou X; Chen Y; Zhang T; Chen H; Wang Y; Li X
Eur J Med Chem; 2023 Dec; 262():115915. PubMed ID: 37948955
[TBL] [Abstract][Full Text] [Related]
25. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
[TBL] [Abstract][Full Text] [Related]
26. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
[TBL] [Abstract][Full Text] [Related]
27. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
[TBL] [Abstract][Full Text] [Related]
28. Dual PI3Kδγ inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282.
Verma MK; Samant C; Kale R; Patra S; Mahajan N; Gholve MK; Marisetti A; Sunkara B; Naik A; Shingare M; Reddy M; Bokare AM; Akarte A; Koul S; Nigade PB; Patil VB; Modi D; Ahirrao P; Pawar S; Kuldharan S; Dinchhana L; Mehta M; Gundu J; Jana N; Vidhate P; Mahangare SJ; Shukla MR; Goel RN; Bhonde M; Kamboj RK; Palle VP
Biochem Biophys Res Commun; 2022 Dec; 637():267-275. PubMed ID: 36410276
[TBL] [Abstract][Full Text] [Related]
29. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways.
He W; Xu Z; Song D; Zhang H; Li B; Gao L; Zhang Y; Feng Q; Yu D; Hu L; Chen G; Tao Y; Wu X; Shi J; Zhu W
Life Sci; 2020 Feb; 243():117249. PubMed ID: 31926247
[TBL] [Abstract][Full Text] [Related]
31. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
32. An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors.
Wu D; Yan Y; Wei T; Ye Z; Xiao Y; Pan Y; Orme JJ; Wang D; Wang L; Ren S; Huang H
Cell Rep; 2021 Feb; 34(7):108744. PubMed ID: 33596421
[TBL] [Abstract][Full Text] [Related]
33. The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma.
Li M; Hu Y; Wang J; Xu Y; Hong Y; Zhang L; Luo Q; Zhen Z; Lu S; Huang J; Zhu J; Zhang Y; Que Y; Sun F
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38063204
[TBL] [Abstract][Full Text] [Related]
34. A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy.
Fan F; Liu P; Bao R; Chen J; Zhou M; Mo Z; Ma Y; Liu H; Zhou Y; Cai X; Qian C; Liu X
Cancer Res; 2021 Dec; 81(24):6233-6245. PubMed ID: 34711611
[TBL] [Abstract][Full Text] [Related]
35. Repurposing dasatinib for diffuse large B cell lymphoma.
Scuoppo C; Wang J; Persaud M; Mittan SK; Basso K; Pasqualucci L; Rabadan R; Inghirami G; Grandori C; Bosch F; Dalla-Favera R
Proc Natl Acad Sci U S A; 2019 Aug; 116(34):16981-16986. PubMed ID: 31383760
[TBL] [Abstract][Full Text] [Related]
36. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.
Mensah AA; Kwee I; Gaudio E; Rinaldi A; Ponzoni M; Cascione L; Fossati G; Stathis A; Zucca E; Caprini G; Bertoni F
Oncotarget; 2015 Mar; 6(7):5059-71. PubMed ID: 25671298
[TBL] [Abstract][Full Text] [Related]
37. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
38. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
39. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
40. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
